脂质组学揭示Alport综合征中关键脂质通路改变
研究采用液相色谱-质谱联用技术分析常染色体显性Alport综合征(ADAS)和X连锁Alport综合征(XLAS)患者血浆与尿液脂质,并与糖尿病肾脏病(DKD)及健康对照比较,发现AS存在鞘脂分解代谢失衡、神经酰胺过载及脂肪酸β氧化受损,与DKD共享脂毒性环境但具有疾病特异性适应,特定脂质可多变量预测肾脏结局。
要点
- AS血浆和尿液分别注释580和203种脂质,与对照相比显示鞘脂分解代谢失衡和神经酰胺过载。
- AS与DKD共享神经酰胺升高和脂肪酸代谢紊乱的脂毒性环境,但AS以鞘磷脂耗竭为特征。
- 尿己糖基神经酰胺18:0(3O)/24:0(2OH)和酰基肉碱12:0被鉴定为关键脂质。
核心结论
- AS存在独特的脂质组学紊乱,并与DKD共享脂毒性机制,为减轻足细胞损伤和延缓AS进展提供了新的潜在治疗靶点。
研究设计与样本
- 研究比较常染色体显性AS(ADAS)和X连锁AS(XLAS)患者与DKD患者及健康对照的血浆和尿液脂质组。
- 采用液相色谱-质谱联用(MS)技术,血浆和尿液分别注释580和203种脂质。
- 使用火山图和受试者工作特征(ROC)分析(曲线下面积[AUC]≥0.80)鉴定关键脂质,并对特定脂质种类进行肾脏结局的多变量预测。
主要发现
- 与对照相比,AS显示鞘脂(SL)分解代谢失衡、神经酰胺(Cer)过载和脂肪酸(FA)β氧化受损。
- AS还显示磷脂和胆固醇失衡,提示ATP结合盒转运体A1亚型(ABCA1)介导的脂质外流受损和线粒体功能障碍。
- 与DKD比较显示共享脂毒性环境伴Cer升高和FA代谢紊乱,但DKD表现为严重ABCA1功能障碍和显著磷脂或胆固醇紊乱,而AS表现为显著鞘磷脂(SM)耗竭。
- 鉴定的关键脂质包括尿己糖基神经酰胺(HexCer)18:0(3O)/24:0(2OH)和酰基肉碱(CAR)12:0,特定脂质种类对肾脏结局的多变量预测支持这些发现。
关键数值与推荐
- 血浆和尿液分别注释580和203种脂质。
- ROC分析采用AUC≥0.80鉴定关键脂质。
- 关键脂质为尿HexCer 18:0(3O)/24:0(2OH)和CAR 12:0。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Alport syndrome (AS) is a hereditary kidney disease from COL4A3-5 pathogenic variants causing glomerular basement membrane abnormalities. Although genetic and structural aspects are known, mechanisms linking collagen IV defects to podocyte injury are unclear. Lipotoxicity and lipid dysregulation likely mediate podocyte damage in AS, similar to diabetic kidney disease (DKD). METHODS: We sought to identify plasma and urine lipid alterations in autosomal dominant AS (ADAS) and X-linked AS (XLAS) compared with DKD and healthy controls. Using liquid chromatography coupled to mass spectrometry (MS), we annotated 580 and 203 lipid species in plasma and urine, respectively. Volcano plot and receiver operating characteristic (ROC) analyses (area under the curve [AUC] ≥ 0.80) were used to identify key lipids and highlight relevant lipotoxic pathways. Multivariate prediction of renal outcomes by specific lipid species was further performed. RESULTS: Compared with controls, AS exhibited unbalanced sphingolipid (SL) catabolism, ceramide (Cer) overload, and impaired fatty acid (FA) β-oxidation, alongside phospholipid and cholesterol imbalances suggestive of compromised isoform A1 of adenosine triphosphate-binding cassette transporter (ABCA1)-mediated lipid efflux and mitochondrial dysfunction. Comparisons with DKD indicated a shared lipotoxic environment with Cer elevation and disrupted FA metabolism. However, disease-specific adaptations emerged, with severe ABCA1 dysfunction and marked phospholipid or cholesterol derangements in DKD, whereas AS showed pronounced sphingomyelin (SM) depletion. Key lipids identified included urinary hexosylceramide (HexCer) 18:0(3O)/24:0(2OH) and acylcarnitine (CAR) 12:0. These findings were supported by multivariate prediction of renal outcomes by specific lipid species. CONCLUSION: These findings demonstrate that AS involves distinct lipidomic disruptions and underscore shared lipotoxic mechanisms with DKD. This improved understanding of disease-specific lipid imbalances provides new potential therapeutic targets to mitigate podocyte injury and slow progression of AS.
引用
- Requena B, Shabaka A, Lanzon B, et al. Lipidomics Unveils Critical Lipid Pathway Shifts in Alport Syndrome. Kidney Int Rep. 2025. PMID: 40814624. doi:10.1016/j.ekir.2025.05.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。